Companies / PYC

PYC THERAPEUTICS LIMITED

ASX:PYCPharmaceuticals, Biotechnology & Life Sciences
983.5M shares on issueASX (delayed) · as of 28 July 2026$1.70price · delayed$1.63Bmarket cap · indicative
C
Dilution grade

Share count grew 82% in 24 months; 3 cash raises in 24 months; 0% of shares in the money

Cash runway39.7 quarters of funding
Share-count growth (24m)82.3%
Raise cadence (24m)3 cash raises
Options & rights overhang0.8% of sharesconsolidation-adjusted
In-the-money supply0.0% of sharesconsolidation-adjusted
Pending proposed issuesnone

PYC THERAPEUTICS LIMITED's ordinary share count grew 82.3% between February 2025 and April 2026, to 984M shares; the reported share count is adjusted for a consolidation on November 2024 described as an "approximately 1-for-1.3 share consolidation." The company raised capital three times in the 24-month window for total disclosed proceeds of A$891.8M, most recently A$600.0M in January 2026. Options and rights on issue could convert into 8M new shares, equal to 0.8% of the current share count, with the nearest expiry in October 2026 and 0% in the money. At the March 2026 quarter the company reported A$645.2M in cash, equal to 39.7 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.8%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
39.7 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-1.3 consolidation (21 Nov 2024). Latest count 983.5M per ASX (delayed) (28 July 2026).
575.2M725.1M875.0MDec 24Sept 25July 26Cash raise · 30 Jan 2026Cash raise · 17 Feb 2025Cash raise · 14 Feb 2025

Cash runway

39.7 qtrs
More than four quarters of funding at the recent spend rate.
$645.2M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
20 July 20263H · cancellationPYC : ORDINARY FULLY PAID983.5MAppendix 3H
17 June 20263H · cancellationPYC : ORDINARY FULLY PAID983.5MAppendix 3H
11 May 20263H · cancellationPYC : ORDINARY FULLY PAID983.5MAppendix 3H
28 Apr 20262A · quoted issuePYC : ORDINARY FULLY PAID983.5MAppendix 2A
9 Mar 20262A · quoted issuePYC : ORDINARY FULLY PAID983.3MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 1 in the last 12 months

$600.0M
Capital raise
30 Jan 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

consolidation-adjusted Figures rebased for the share consolidation in the last 24 months.

0.8%
Total overhang · of current shares
0.0%
In the money · at current price
7.5M
Potential new shares
Oct 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
24 Mar 2026Dr Rohan HockingsBuy83k—$100k3Y notice
6 Mar 2026Dr Rohan HockingsBuy80k—$120k3Y notice
6 Mar 2026Professor Ian ConstableBuy123k—$185k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026$PPKD - Safety Committee Approves Dose Escalation
20 July 2026$PADOA Program Update
20 July 2026Notification of cessation of securities - PYC
19 July 2026Presentation At 2026 PMS Foundation Family Conference
15 July 2026Results of Meeting
7 July 2026Grant of Patents by the US Patent Office
6 July 2026Appointment of Chief Financial Officer
17 June 2026Notification of cessation of securities - PYC
16 June 2026Becoming a substantial holder
15 June 2026Company Secretary Appointment/Resignation
12 June 2026Notice of General Meeting/Proxy Form
26 May 2026Change to CEO remuneration
21 May 20262026 Q2 Investor Webinar Presentation
18 May 2026Ceasing to be a substantial holder
11 May 2026Investor Webinar
11 May 2026Notification of cessation of securities - PYC
6 May 2026$PPKD - Initiation of Multiple Dose Clinical Trial
3 May 2026$PPresentation of Ophthalmology Clinical Trial Data at ARVO
28 Apr 2026Exercise of Options and Cleansing Notice
28 Apr 2026Application for quotation of securities - PYC

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.